Résumés
Résumé
L’endothéline-1 (ET-1) et l’angiotensine II (AngII) sont des peptides vasoactifs, mais aussi mitogènes et pro-angiogéniques. Tous deux exercent leurs actions par l’intermédiaire de récepteurs couplés aux protéines G : ETA-R et ETB-R pour ET-1 ; AT1R et AT2R pour AngII. L’expression des composants des systèmes ET-1 et AngII dans diverses tumeurs présente généralement une ou plusieurs des caractéristiques suivantes : surexpression du peptide et/ou du récepteur, modification du sous-type de récepteur exprimé et localisation nucléaire du récepteur. ET-1 et AngII agissent sur les différentes étapes de la progression tumorale, et l’utilisation d’antagonistes spécifiques de leurs récepteurs, ou d’inhibiteurs de leur synthèse, est efficace pour ralentir la croissance tumorale in vitro et in vivo dans différents modèles animaux. Des essais cliniques utilisant des antagonistes d’ETA-R donnent des résultats encourageants pour le traitement antitumoral, et une approche similaire ayant pour objectif de bloquer ETB-R ou AT1R est envisageable. De plus, une thérapie combinée ciblant les deux systèmes, ET-1 et AngII, pourrait se révéler bénéfique pour le traitement de tumeurs fortement angiogéniques.
Summary
Endothelin-1 (ET-1) and angiotensin II (AngII), two potent vasoactive peptides involved in the regulation of cardiovascular homeostasis, also induce mitogenic and pro-angiogenic responses in vitro and in vivo. Both peptides are produced by cleavage of inactive precursors by metalloproteases (endothelin-converting enzyme and angiotensin-converting enzyme, respectively) and activate two subtypes of membrane receptors (ETA-R and ETB-R for ET-1, AT1R and AT2R for AngII) that all belong to the superfamily of G-protein coupled receptors. There is increasing evidence that ETA-R, ETB-R and AT1R are expressed in a variety of cancer cells and tissues, and may play a role on tumor growth, angiogenesis and invasion in vivo. This review summarizes the similarities and differences between the ET-1 and AngII systems with regard to their reported effects on various aspects of cancer. In addition to being expressed on vascular endothelium, ET-1 and AngII receptors participate in tumor angiogenesis through the production of the angiogenic factor VEGF. Furthermore, recent clinical studies indicate that a selective ETA-R antagonist has beneficial effects in prostate cancer, suggesting that a similar approach using ETB-R and AT1R blockers might be envisioned. Experimental data presented here suggest that a combined therapy targeting both ET-1 and AngII systems may prove valuable for future treatments of highly angiogenic tumors.
Parties annexes
Références
- 1. Lotersztajn S. Les endothélines. Med Sci (Paris) 1993 ; 9 : 1084-93.
- 2. Cazaubon S, Couraud PO. Nitric oxide and endothelin at the blood-brain barrier. In : Pardrige W, ed. Introduction to the blood-brain barrier. New York Raven Press Ltd, 1998 : 338-44.
- 3. Nouet S, Nahmias C. Signal transduction from the angiotensin II AT2 receptor. Trends Endocrinol Metab 2000 ; 11 : 1-6.
- 4. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995 ; 1 : 944-9.
- 5. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis : emerging role in cancer. Nat Rev Cancer 2003 ; 3 : 110-6.
- 6. Grant K, Loizidou M, Taylor I. Endothelin-1 : a multifunctional molecule in cancer. Br J Cancer 2003 ; 88 : 163-6.
- 7. Deshayes F, Nahmias C. Angiotensin II receptors : a new role in cancer ? Trends Endocrinol Metab 2005 ; 16 : 293-9.
- 8. Egidy G, Baviera E, Ciuffo G, et al. Localization of the endothelin system in aldosterone-producing adenomas. Hypertension 2001 ; 38 : 1137-42.
- 9. Juillerat-Jeanneret L, Celerier J, Chapuis Bernasconi C, et al. Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br J Cancer 2004 ; 90 : 1059-68.
- 10. Anguelova E, Beuvon F, Leonard N, et al. Functional endothelin ET(B) receptors are selectively expressed in human oligodendrogliomas. Brain Res Mol Brain Res 2005 ; 137 : 77-88.
- 11. Lazarini F, Strosberg AD, Couraud PO, Cazaubon SM. Coupling of ETB endothelin receptor to mitogen-activated protein kinase stimulation and DNA synthesis in primary cultures of rat astrocytes. J Neurochem 1996 ; 66 : 459-65.
- 12. Lahav R, Heffner G, Patterson PH. An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci USA 1999 ; 96 : 11496-500.
- 13. Cook JL, Zhang Z, Re RN. In vitro evidence for an intracellular site of angiotensin action. Circ Res 2001 ; 89 : 1138-46.
- 14. Boivin B, Chevalier D, Villeneuve LR, et al. Functional endothelin receptors are present on nuclei in cardiac ventricular myocytes. J Biol Chem 2003 ; 278 : 29153-63.
- 15. Egami K, Murohara T, Shimada T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 2003 ; 112 : 67-75.
- 16. Fujita M, Hayashi I, Yamashina S, et al. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 2005 ; 26 : 271-9.
- 17. Arrieta O, Guevara P, Escobar E, et al. Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer 2005 ; 92 : 1247-52.
- 18. Fischer O, Hart S, Gschwind A, Ullrich A. EGFR signal transactivation in cancer cells. Biochem Soc Trans 2003 ; 31 : 1203-8.
- 19. Elbaz N, Bedecs K, Masson M, et al. Functional trans-inactivation of insulin receptor kinase by growth-inhibitory angiotensin II AT2 receptor. Mol Endocrinol 2000 ; 14 : 795-804.
- 20. Nouet S, Amzallag N, Li J, et al. Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. J Biol Chem 2004 ; 279 : 28989-97.
- 21. Bagnato A, Spinella F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab 2003 ; 14 : 44-50.
- 22. Escobar E, Rodriguez-Reyna TS, Arrieta O, Sotelo J. Angiotensin II, cell proliferation and angiogenesis regulator : biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 2004 ; 2 : 385-99.
- 23. Rosano L, Spinella F, Di Castro V, et al. Endothelin receptor blockade inhibits molecular effectors of Kaposi’s sarcoma cell invasion and tumor growth in vivo. Am J Pathol 2003 ; 163 : 753-62.
- 24. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003 ; 100 : 10954-9.
- 25. Chiao JW, Moonga BS, Yang YM, et al. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 2000 ; 83 : 360-5.
- 26. Volpert OV, Ward WF, Lingen MW, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996 ; 98 : 671-9.
- 27. Prontera C, Mariani B, Rossi C, et al. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer 1999 ; 81 : 761-6.
- 28. Lindberg H, Nielsen D, Jensen B, et al. Angiotensin converting enzyme inhibitors for cancer treatment ? Acta Oncol 2004 ; 43 : 142-52.
- 29. Miyajima A, Kosaka T, Asano T, et al. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 2002 ; 62 : 4176-9.
- 30. Fujita M, Hayashi I, Yamashina S, et al. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 2002 ; 294 : 441-7.
- 31. Suganuma T, Ino K, Shibata K, et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 2005 ; 11 : 2686-94.
- 32. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer : a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003 ; 21 : 679-89.
- 33. Carducci MA, Nelson JB, Bowling MK, et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas : safety and pharmacokinetics. J Clin Oncol 2002 ; 20 : 2171-80.
- 34. Lever A, Hole D, Gillis C, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer ? Lancet 1998 ; 352 : 179-84.
- 35. Friis S, Sorensen HT, Mellemkjaer L, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer : a population-based cohort study in Denmark. Cancer 2001 ; 92 : 2462-70.